“We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain,” asserts one small/mid-cap stock strategist cited in today’s article, which proceeds to highlight two penny stocks that boast “Strong Buy” consensus ratings and upside potential over 200%. For these two penny stocks, CLICK HERE.
What’s the best proxy for the trends that can help you make money? The answer may be the 50-day moving average, which the author of today’s article advises “is in the goldilocks zone of not being too short or too long.” Using the example of a potentially game-changing stock from the green energy sector, he outlines how traders can use…
“To me, this is the biggest contrarian bet you can make today. If you’ve got the guts to make the trade, it could lead to massive upside from here,” says the author of today’s article in regards to the investment opportunity he outlines – one that involves an investment that, being cheap, hated and in the start of an uptrend,…
One of the strongest biotechs out there, a diamond in the rough, and a high-risk, high-reward play make up the three biotech stocks identified by the author of today’s article as top picks for 2021 for investors looking for even better biotech returns than those offered by broad biotech ETFs such as the SPDR S&P Biotech ETF. For a look…
While biotech stocks have been hot over the last year, today’s article notes that another group of stocks have been trading like biotech companies of late: psychedelic stocks. In fact, a slew of psychedelic stocks have posted triple-digit returns over the last year – and with the impending release of studies examining the use of psychedelics to treat mental health…
While many are hopeful that 2021 will bring better times than 2020, there’s much we don’t know about what this new year has in store. One thing we do know, points out the author of today’s article, is that “there will be new problems needing more tech, and tech investors are ever-ready to pounce when that time comes.” As such,…
While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes…
Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to…
With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks…
Which biotechs are the hottest acquisition targets heading into 2021 – and which large drugmakers are likely to seek to acquire them? Seventy-eight members of the biopharma investment community offered their opinions in a recent Bloomberg Intelligence survey – and today’s article outlines their biotech acquisition predictions. For more, CLICK HERE.